BDTX (Black Diamond Therapeutics) Moat Score: 2/10 (As of Jul. 01, 2026)


BDTX Black Diamond Therapeutics Inc BDTX
37 GF Score
Price $1.84
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Moat Score?

Black Diamond Therapeutics BDTX 37 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates BDTX with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, Black Diamond Therapeutics ranks better than 58.07% on this metric.

Black Diamond Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Black Diamond Therapeutics has No Moat: Black Diamond Therapeutics has limited market leadership and lacks significant customer switching costs or brand strength. The biotech sector's competitive nature and the company's early-stage development status contribute to its weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Black Diamond Therapeutics might have No Moat - Very weak/transient advantages.

Black Diamond Therapeutics  (NAS:BDTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Black Diamond Therapeutics Moat Score Related Terms

BDTX vs CGTX, PMN, PTHS: Moat Score Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Moat Score falls into.


BDTX
37GF Score
Black Diamond Therapeutics Inc BDTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Black Diamond Therapeutics (BDTX) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Black Diamond Therapeutics ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Black Diamond Therapeutics' Moat Score too high?
Black Diamond Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Black Diamond Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Black Diamond Therapeutics ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Black Diamond Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' Moat Score compare to CGTX and PMN?
According to the Biotechnology industry distribution chart, Black Diamond Therapeutics ranks #587 out of 1400 companies for Moat Score. This puts Black Diamond Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Black Diamond Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Black Diamond Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Black Diamond Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Black Diamond Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
37GF Score

Get the complete analysis for BDTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.84
Price